Recent Updates
Recently added Catalysts
UTHR Positive Sentiment

United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference

Key Takeaway: United Therapeutics Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Dr. Martine Rothblatt will provide an overview and update during the session. The presentation will be accessible via a live webcast, with an archived version available afterward. The company emphasizes its mission to innovate for patient needs.
Price reaction · baseline $496.72 (2026-01-02 close) · hit pre-market · clean, no other UTHR news in the window
day 0 close · peak
-1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • United Therapeutics is presenting at a prestigious healthcare conference.
  • The company is committed to addressing unmet medical needs.
  • They are the first public benefit corporation in the biotech sector.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+21%
120-day peak, hindsight
Typical move
10.8%
average across 6 past catalysts
Lead asset
UBT251
Phase 2 · Obesity &Amp; Overweight

Full Press Release Details

SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq:UTHR) announced today thatDr. Martine Rothblatt, Chairperson and Chief Executive Officer, will present a company overview and update on Monday, January 12, 2026, from 1:30 to 2:10 p.m. PST, at the 44thAnnual J.P. Morgan Healthcare Conference in San Francisco.
The presentation can be accessed via a live webcast on the United Therapeutics website athttps://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 30 days.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.
You can learn more about what it means to be a PBC here:unither.com/pbc.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of January 5, 2026, and assume no obligation to update or revise the information contained in this press release whether because of new information, future events or any other reason.

Frequently Asked Questions

When will United Therapeutics present at the conference?

United Therapeutics will present on January 12, 2026, from 1:30 to 2:10 p.m. PST.

How can I access the presentation?

The presentation can be accessed via a live webcast on the United Therapeutics website.

What is the focus of United Therapeutics?

United Therapeutics focuses on developing novel pharmaceutical therapies and expanding organ availability.

Who is the CEO of United Therapeutics?

Dr. Martine Rothblatt is the Chairperson and CEO of United Therapeutics.

Last updated: Jan 5, 2026